Page 50 - GTM-3-3

Global Translational Medicine Ocular changes in Alzheimer’s disease

5. Ascaso FJ, Cruz N, Modrego PJ, et al. Retinal alterations 16. Blennow K, Hampel H, Weiner M, Zetterberg H.
in mild cognitive impairment and Alzheimer’s disease: Cerebrospinal fluid and plasma biomarkers in Alzheimer
An optical coherence tomography study. J Neurol. disease. Nat Rev Neurol. 2010;6(3):131-144.
2014;261:1522-1530.
doi: 10.1038/nrneurol.2010.4
doi: 10.1007/s00415-014-7374-z
17. Xia X, Qin Q, Peng Y, Wang M, Yin Y, Tang Y. Retinal
6. Asanad S, Ross-Cisneros FN, Nassisi M, Barron E, examinations provides early warning of Alzheimer’s disease.
Karanjia R, Sadun AA. The retina in Alzheimer’s disease: J Alzheimers Dis. 2022;90(4):1341-1357.
Histomorphometric analysis of an ophthalmologic doi: 10.3233/JAD-220596
biomarker. Invest Ophthalmol Vis Sci. 2019;60:1491-1500.
18. Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid
doi: 10.1167/iovs.18-25966
tau levels in neurodegenerative diseases with distinct
7. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The tau-related pathology. Biochem Biophys Res Commun.
epidemiology of Alzheimer’s disease modifiable risk factors 1997;236(2):262-264.
and prevention. J Prev Alzheimers Dis. 2021;8(3):313-321.
doi: 10.1006/bbrc.1997.6908
doi: 10.14283/jpad.2021.15
19. Xie F, Peng F. Radiopharmaceuticals for assessment of
8. Public Health Agency of Canada. Dementia: Overview; 2024. altered metabolism and biometal fluxes in brain aging and
Available from: https://www.canada.ca/en/publichealth/ Alzheimer’s disease with positron emission tomography.
services/diseases/dementia.html [Last accessed on J Alzheimers Dis. 2017;59(2):527-536.
2024 Apr 18].
doi: 10.3233/JAD-170280
9. Public Health Agency of Canada. Dementia in Canada; 2024. 20. Surguchov A, McMahan B, Masliah E, Surgucheva F.
Available from: https://www.canada.ca/en/publichealth/ Synucleins in ocular tissues. J Neurosci Res. 2001;65(1):
services/publications/diseases-conditions/dementia.html
[Last accessed on 2024 Apr 18]. 68-77.
doi: 10.1002/jnr.1129
10. Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and
national burden of Alzheimer’s disease and other dementias, 21. Romaus-Sanjurjo D, Regueiro U, López-López M, et al.
1990-2016: A systematic analysis for the Global Burden of Alzheimer’s disease seen through the eye: Ocular alterations
Disease Study 2016. Lancet Neurol. 2019;18(1):88-106. and neurodegeneration. Int J Mol Sci. 2022;23(5):2486.
doi: 10.1016/S1474-4422(18)30403-4 doi: 10.3390/ijms23052486
11. Ashok A, Singh N, Chaudhary S, et al. Retinal degeneration 22. Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid
and Alzheimer’s disease: An evolving link. Int J Mol Sci. pathology and proof-of-concept imaging trial in Alzheimer’s
2020;21(19):7290. disease. JCI Insight. 2017;2(16):e93621.
doi: 10.3390/ijms21197290 doi: 10.1172/jci.insight.93621
12. Sultan S, Al-Hammadi M, Alshareef A, Al-Barakati AM, 23. Sidiqi A, Wahl D, Lee S, et al. In vivo retinal fluorescence
Al-Huthali RK, Al-Jahdali NH. An update on treatment of imaging with curcumin in an Alzheimer mouse model.
Alzheimer disease-a literature review. Eur J Pharm Med Res. Front Neurosci. 2020;14:713.
2018;205(7):8-18.
doi: 10.3389/fnins.2020.00713
13. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. 24. Aumann S, Donner S, Fischer J, Müller F. Optical Coherence
Neuroimaging markers for the prediction and early Tomography (OCT): Principle and technical realization. In:
diagnosis of Alzheimer’s disease dementia. Trends Neurosci. Bille JF, editor. High Resolution Imaging in Microscopy and
2011;34(8):430-442.
Ophthalmology: New Frontiers in Biomedical Optics. Cham,
doi: 10.1016/j.tins.2011.05.005 CH: Springer International Publishing; 2019. p. 59-85.
14. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive doi: 10.1007/978-3- 030-16638-0_3
impairment--beyond controversies, towards a consensus: 25. Gharbiya M, Trebbastoni A, Parisi F, et al. Choroidal
Report of the international working group on mild cognitive thinning as a new finding in Alzheimer’s disease: Evidence
impairment. J Intern Med. 2004;256(3):240-246.
from enhanced depth imaging spectral domain optical
doi: 10.1111/j.1365-2796.2004.01380.x coherence tomography. J Alzheimer Dis. 2014;40(4):
907-917.
15. Weller J, Budson A. Current understanding of Alzheimer’s
disease diagnosis and treatment. F1000Res. 2018;7:F1000 doi: 10.3233/JAD-132039
Faculty Rev-1161.
26. Cunha JP, Proença R, Dias‐Santos A, et al. Choroidal
doi: 10.12688/f1000research.14506.1 thinning: Alzheimer’s disease and aging. Alzheimers Dement

Volume 3 Issue 3 (2024) 11 doi: 10.36922/gtm.4094